Boston University developed a methodology to evaluate the impact of Novartis Access in Kenya. Peter C. Rockers tells us about the ongoing study.

In Australia, a country where skin cancer rates remain high, cancer survivor Malcolm Caddies is on a mission to prevent the risks of sun exposure.

New NIBR President Jay Bradner shares on drug discovery, his leadership style and what’s next for his career in biomedical research.

A Novartis experimental drug in clinical trial aims to block liver cancer growth

Kristen Harrington-Smith discusses her work as Vice President and Head of CAR-T US at Novartis Oncology.

Team uncovers a potential therapeutic approach for patients deficient in a protein called Shank3.

The modernization and miniaturization of pharmaceutical production could expand the range of ingredients medicinal chemists use to make new drugs.

Immunotherapy for cancer is on the brink of breakthroughs. Learn how NIBR have high expectations for this medical science.

An interview with Thierry Diagana, Head of the Novartis Institute for Tropical Diseases.